Moti Barda

Renalsense Ltd. is a privately owned Israeli medical device company that specializes in real-time renal diagnostics. The company is based in Jerusalem, Israel. The company's first product, Clarity RMS, provides continuous and automatic monitoring of urine flow for early detection of acute kidney injury (AKI). Renalsense aims to improve critical care management in the ICU and peri-operative setting by providing additional real-time parameters and expanded diagnostic capabilities in their next-generation products. Renalsense was founded in 2009 by Avi Kleiman and Mor Grinstein, and Avi Kleiman has been the CEO since then.

Renalsense Ltd. is a privately owned Israeli medical device company that specializes in real-time renal diagnostics. The company is based in Jerusalem, Israel. The company's first product, Clarity RMS, provides continuous and automatic monitoring of urine flow for early detection of acute kidney injury (AKI). Renalsense aims to improve critical care management in the ICU and peri-operative setting by providing additional real-time parameters and expanded diagnostic capabilities in their next-generation products. Renalsense was founded in 2009 by Avi Kleiman and Mor Grinstein, and Avi Kleiman has been the CEO since then.

Renalsense Ltd. is a privately owned Israeli medical device company that specializes in real-time renal diagnostics. The company is based in Jerusalem, Israel. The company's first product, Clarity RMS, provides continuous and automatic monitoring of urine flow for early detection of acute kidney injury (AKI). Renalsense aims to improve critical care management in the ICU and peri-operative setting by providing additional real-time parameters and expanded diagnostic capabilities in their next-generation products. Renalsense was founded in 2009 by Avi Kleiman and Mor Grinstein, and Avi Kleiman has been the CEO since then.

Renalsense Ltd. is a privately owned Israeli medical device company that specializes in real-time renal diagnostics. The company is based in Jerusalem, Israel. The company's first product, Clarity RMS, provides continuous and automatic monitoring of urine flow for early detection of acute kidney injury (AKI). Renalsense aims to improve critical care management in the ICU and peri-operative setting by providing additional real-time parameters and expanded diagnostic capabilities in their next-generation products. Renalsense was founded in 2009 by Avi Kleiman and Mor Grinstein, and Avi Kleiman has been the CEO since then.